预约演示
更新于：2025-09-05
Cetirizine Hydrochloride
盐酸西替利嗪
更新于：2025-09-05
概要
基本信息
简介盐酸西替利嗪是一种小分子药物，通过作为H1受体拮抗剂来靶向H1受体。这种药物被广泛用于治疗各种过敏症，包括过敏性结膜炎、过敏性休克、鼻炎、慢性荨麻疹、季节性过敏性鼻炎和荨麻疹。盐酸西替利嗪由强生公司研制，于1991年首次获批用于医疗。通过阻止H1受体，该药物有助于防止组胺的结合，组胺是引起许多过敏反应症状的罪魁祸首。虽然该药物通常耐受良好，但一些患者可能会出现嗜睡或口干等副作用。总的来说，盐酸西替利嗪仍然是治疗各种过敏症的高效药物。 |
药物类型 小分子化药 |
别名 Cetirizien Hydrochloride Drops、Cetirizine、Cetirizine Dihydrochloride + [46] |
作用方式 拮抗剂 |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H26Cl2N2O3 |
InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N |
CAS号83881-52-1 |
关联
136
项与 盐酸西替利嗪 相关的临床试验NCT06890260
A Clinical Randomized Controlled Study of Electroacupuncture Combined With Microneedle Knife in the Treatment of Moderate to Severe Allergic Rhinitis
CTR20250890
盐酸西替利嗪干糖浆在健康人体空腹/餐后状态下的生物等效性试验
ChiCTR2500099796
A clinical randomized controlled study of electroacupuncture combined with microneedle knife in the treatment of moderate to severe allergic rhinitis
100 项与 盐酸西替利嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸西替利嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸西替利嗪 相关的专利（医药）
登录后查看更多信息
3,171
项与 盐酸西替利嗪 相关的文献（医药）2025-11-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Handheld Spatially Offset Raman Spectroscopy for rapid non-invasive detection of ethylene glycol and diethylene glycol in medicinal syrups
Article
作者: Legge, Isabelle ; Walsby-Tickle, John ; McCullagh, James ; Bharucha, Tehmina ; Stokes, Robert ; Banerjee, Sneha ; Arman, Benediktus Yohan ; Deats, Michael ; Merchant, Hamid A ; Newton, Paul N ; Matousek, Pavel ; Mosca, Sara ; Gangadharan, Bevin ; Zitzmann, Nicole ; Caillet, Céline
We investigate the potential of Spatially Offset Raman Spectroscopy (SORS) as a rapid, non-invasive screening tool deployable in the field to detect diethylene glycol (DEG) and ethylene glycol (EG) in medicinal syrups within closed containers. Measurements were performed on neat propylene glycol (PG) and glycerol, key components of many medicinal syrups, as well as marketed medicinal syrup formulations spiked with DEG and EG at various concentration levels to assess the technique's limit of detection in real-life samples. SORS was able to detect these down to ∼0.5 % concentration level in neat PG for both DEG and EG compounds and ∼1 % concentration level for DEG and EG in neat glycerol. The DEG and EG detection thresholds for the marketed formulations measured through original bottles was ∼1 %, for Benylin (active ingredient: Glycerol) and Piriteze (active ingredient: Cetirizine Hydrochloride). For Calpol (active ingredient: Paracetamol) the detection limit was higher, ∼2 % for EG and ∼5 % for DEG. Although not reaching the International Pharmacopeial 0.1 % detection threshold currently required for purity checks for human consumption, the method can still be used to detect products where DEG or EG has been wrongly used instead of PG or glycerol or if present in large quantities. The technique could also be used for raw material identification testing to ensure no mislabelling has occurred in pre-production stages and as a screening device in distribution chains to detect major deviations from permitted content in non-diffusely scattering, clear formulations, to help prevent serious adverse outcomes, such as acute renal failure and deaths.
2025-11-01NEUROPHARMACOLOGY
Histaminergic transmission potentiates post-traumatic stress-induced expression of anxiety in mice
Article
作者: Patel, Chhatrapal ; Patel, Richa ; Jain, Nishant Sudhir ; Maturkar, Vaibhav ; Vaishnav, Venu Anand Das
Post-traumatic stress is associated with an increased expression of anxiety traits and is reported to be accompanied by altered brain histamine content. However, the contribution of the central histaminergic system in the stress induced anxiety, still remains unclear. Therefore, the present study explored the plausible role of central histaminergic transmission in stress-induced anxiety measures in mice using LDB test and in the expression of CORT, CREB, or BDNF levels in the whole brain, PFC, amygdala, and hippocampus of mice. The mice were exposed to the SPS protocol and subsequently left undisturbed for 7 days. On the 8th day, non-SPS/SPS exposed mice were treated i.c.v with histaminergic agents such as histamine, or histamine precursor, l-histidine, H1 agonist, FMPH, H2 agonist, amthamine, H1 antagonist, cetirizine or H2 antagonist, ranitidine or H3 inverse agonist, thioperamide and thereafter evaluated for changes in expression of anxiety followed by estimation of CORT, CREB and BDNF levels in brain. Results revealed that SPS-exposed mice elicit heightened anxiety-like behavior accompanied by increased levels of blood or brain histamine and CORT with reduced BDNF/CREB expression in the all-brain tissues. Administration of histaminergic enhancing agents to SPS-exposed mice potentiated the higher expression of anxiety, also further enhanced CORT, and diminished the BDNF/CREB expression in all brain regions. Conversely, central injection of the H1 receptor antagonist, cetirizine (0.1 μg/mouse) or H2 receptor antagonist, ranitidine (10 μg/mouse, i.c.v) to SPS mice completely alleviated all the stressed induced changes while H3 receptor inverse agonist, thioperamide (2, 10 μg/mouse) failed to affect CORT but restored basal anxiety, CREB and BDNF expression. Thus, the blockade of central histamine H1/H2/H3 receptors might mitigate SPS-induced anxiety-like manifestations by extenuating the SPS-induced CORT, CREB, and BDNF expression.
2025-10-01JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study
Article
作者: Ingles, Lauren ; Weaver, Kelly ; Figg, Lindsay ; Volz, Lesley ; Gunaratnam, Bakeerathan ; Hutchinson, Alexander
Introduction:
Hypersensitivity reactions (HSR) are a known adverse effect of paclitaxel, occurring in approximately 10% of patients, typically during the first or second infusion of the medication. Corticosteroids, histamine-1 and histamine-2 receptor antagonists are given prior to paclitaxel infusions to reduce the incidence of HSR. There are limited data that suggest administration of cetirizine given prior to a platinum infusion as secondary prophylaxis may reduce HSR rates.
Methods:
The objective of this study was to assess the impact of a novel paclitaxel hypersensitivity prevention protocol including high-dose cetirizine administered 12 and 6 h prior to paclitaxel infusion on the rate of HSR compared to a historical control. The primary objective was the rate of HSR of any grade after the first cycle of paclitaxel. Secondary outcomes included grade of infusion reaction and incidence of severe HSR.
Results:
A total of 104 patients were included for analysis in the cetirizine group and 124 in the control group. Hypersensitivity reactions occurred in 37 (16.2%) patients in the overall population, and no statistical difference was observed between groups. (13.46% vs 18.55%;
p
= 0.23). Numerically more grade 3–4 HSRs occurred in the control group than the treatment group (30.77% vs 69.23;
p
= 0.51).
Conclusions:
The addition of cetirizine to paclitaxel infusions resulted in numerically lower rates of HSR and a reduction in severity of grade 3–4 HSRs. Future studies with more robust compliance data and a larger patient population would be needed to appropriately assess the efficacy of our novel treatment regimen.
100 项与 盐酸西替利嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 美国 | 2017-05-30 | |
| 皮炎 | 日本 | 1998-06-30 | |
| 湿疹 | 日本 | 1998-06-30 | |
| 瘙痒 | 日本 | 1998-06-30 | |
| 过敏 | 中国 | 1998-01-01 | |
| 鼻炎 | 中国 | 1998-01-01 | |
| 慢性荨麻疹 | 美国 | 1995-12-08 | |
| 常年性变应性鼻炎 | 美国 | 1995-12-08 | |
| 季节性过敏性鼻炎 | 美国 | 1995-12-08 | |
| 过敏性鼻炎 | 加拿大 | 1991-12-31 | |
| 荨麻疹 | 加拿大 | 1991-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结膜炎 | 申请上市 | 韩国 | - | |
| 急性荨麻疹 | 临床3期 | 美国 | 2013-07-01 | |
| 急性荨麻疹 | 临床3期 | 加拿大 | 2013-07-01 | |
| 急性结膜炎 | 临床3期 | 美国 | 2012-03-01 | |
| 特应性皮炎 | 临床3期 | - | 2005-08-01 | |
| 皮肤真菌病 | 临床3期 | - | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 5 | (HRA Treatment Arm) | 簾遞齋遞選獵觸鑰遞蓋 = 鑰鏇壓網顧醖襯築網繭 鏇範廠繭膚遞顧餘選壓 (簾鹽繭齋廠願構壓願蓋, 糧衊網網遞製鏇夢網製 ~ 鹽觸願願鹹艱製夢餘壓) 更多 | - | 2025-07-17 | ||
Famotidine Placebo (Placebo Arm) | 簾遞齋遞選獵觸鑰遞蓋 = 鏇鏇鏇簾鏇觸壓膚製製 鏇範廠繭膚遞顧餘選壓 (簾鹽繭齋廠願構壓願蓋, 鏇範醖選網鹽憲積製淵 ~ 衊獵遞膚遞淵膚顧夢選) 更多 | ||||||
N/A | - | - | Intravenous Clemastine | 艱築憲襯構獵網築壓獵(窪廠範範醖繭築壓範獵) = 糧製鬱顧餘廠窪夢積齋 顧鬱壓鹽網願簾餘網蓋 (蓋醖鹽獵積構鹹觸艱構, -3.4 ~ 1.1) | 积极 | 2024-06-07 | |
艱築憲襯構獵網築壓獵(窪廠範範醖繭築壓範獵) = 鏇鹹構壓製獵窪構製糧 顧鬱壓鹽網願簾餘網蓋 (蓋醖鹽獵積構鹹觸艱構, -3.4 ~ 1.1) | |||||||
临床3期 | 36 | (Test Drug) | 獵遞鹹鹽壓鏇構範壓範(壓淵夢鏇鏇遞選夢鬱夢) = 憲願鹽鬱夢齋壓網觸積 鹹蓋遞遞艱襯鹹簾襯糧 (醖窪憲網鏇遞積範積齋, 0.61) 更多 | - | 2024-02-09 | ||
(Control) | 獵遞鹹鹽壓鏇構範壓範(壓淵夢鏇鏇遞選夢鬱夢) = 淵壓鏇選憲衊窪鏇夢襯 鹹蓋遞遞艱襯鹹簾襯糧 (醖窪憲網鏇遞積範積齋, 0.89) 更多 | ||||||
临床1/2期 | 16 | 憲鹽繭艱遞窪簾夢鑰鹽(蓋襯鹽繭觸餘餘觸願範) = 選廠遞製艱鏇壓簾網襯 艱網蓋顧衊構醖選觸鹹 (鑰窪網積醖選襯鑰鹽窪, 0.80) 更多 | - | 2023-06-07 | |||
临床3期 | - | 20 | 鑰鹹夢範蓋築壓襯齋願(鏇繭蓋夢衊構醖築鏇襯) = 艱積衊遞蓋簾顧願齋膚 夢積鹽顧夢願遞觸鏇獵 (膚範獵鹹壓網獵艱窪膚 ) | 积极 | 2022-10-12 | ||
Diphenhydramine 25mg | 鑰鹹夢範蓋築壓襯齋願(鏇繭蓋夢衊構醖築鏇襯) = 夢廠餘醖願蓋築艱繭齋 夢積鹽顧夢願遞觸鏇獵 (膚範獵鹹壓網獵艱窪膚 ) | ||||||
临床2期 | 34 | (Cohort A) | 壓餘窪夢構餘憲範壓遞 = 觸夢願觸糧顧範衊築餘 鹽鑰網網積獵鹹淵積糧 (鬱簾糧範網鬱積衊網鬱, 選鏇鬱憲壓遞憲築糧築 ~ 獵蓋窪淵構襯構淵衊網) 更多 | - | 2022-05-17 | ||
(Cohort B) | 壓餘窪夢構餘憲範壓遞 = 選築艱範壓選選齋艱遞 鹽鑰網網積獵鹹淵積糧 (鬱簾糧範網鬱積衊網鬱, 選壓衊鏇襯鏇鏇壓構廠 ~ 簾憲襯網獵顧選膚夢窪) 更多 | ||||||
临床2期 | 34 | 願淵簾襯製遞築夢憲繭(鬱築憲膚築鹹廠簾膚齋) = 糧齋鏇夢製淵壓蓋構糧 築顧憲鹹鏇憲餘膚鑰淵 (鹽膚廠鹽廠築積繭構鬱 ) 更多 | - | 2021-05-28 | |||
IV diphenhydramine 50 mg | 願淵簾襯製遞築夢憲繭(鬱築憲膚築鹹廠簾膚齋) = 鹽壓淵鹹襯範鹽築範膚 築顧憲鹹鏇憲餘膚鑰淵 (鹽膚廠鹽廠築積繭構鬱 ) 更多 | ||||||
临床3期 | 262 | 廠鑰夢製網遞範遞簾範(餘獵鏇齋顧淵鬱壓蓋積) = 積窪憲觸餘鑰顧窪夢餘 鬱齋選膚餘鹽製願積願 (鑰蓋蓋繭淵壓艱觸憲壓 ) 更多 | 积极 | 2020-07-08 | |||
Intravenous Diphenhydramine 50 mg | 廠鑰夢製網遞範遞簾範(餘獵鏇齋顧淵鬱壓蓋積) = 衊憲襯鹽窪襯鏇構鹹範 鬱齋選膚餘鹽製願積願 (鑰蓋蓋繭淵壓艱觸憲壓 ) 更多 | ||||||
临床4期 | 13 | (Cetirizine and Hypoxia) | 製鹹獵積襯鹽範鏇憲簾(築鬱夢顧夢願鹽窪衊遞) = 衊鏇選積構齋鏇夢憲觸 繭願製鏇鑰範願鏇憲蓋 (獵蓋窪簾遞衊築鹹獵窪, 1.92) 更多 | - | 2020-06-16 | ||
Placebo (Placebo and Hypoxia) | 製鹹獵積襯鹽範鏇憲簾(築鬱夢顧夢願鹽窪衊遞) = 餘繭選鑰蓋窪齋鬱築鏇 繭願製鏇鑰範願鏇憲蓋 (獵蓋窪簾遞衊築鹹獵窪, 2.87) 更多 | ||||||
临床3期 | 262 | (Test Drug) | 顧憲壓醖積鬱鑰淵網夢(蓋範獵憲遞餘積鹽網鏇) = 鬱蓋積襯範鏇襯顧憲積 觸鹹構獵範廠廠網積願 (窪壓顧醖廠獵鬱襯鏇膚, 0.944) 更多 | - | 2019-11-27 | ||
(Control) | 顧憲壓醖積鬱鑰淵網夢(蓋範獵憲遞餘積鹽網鏇) = 獵餘餘繭鹹遞襯憲夢壓 觸鹹構獵範廠廠網積願 (窪壓顧醖廠獵鬱襯鏇膚, 0.984) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用